CV date	17/01/2022

Part A. PERSONAL INFORMATION

First and Family name	Jose Antonio García Salcedo		
Social Security, Passport, ID number		Age	
Researcher codes	WoS Researcher ID *(*)*	AAA-9434-2019	
	SCOPUS Author ID*(*)*	6603223188	
	Open Researcher and Contributor ID (ORCID) **	0000-0003-3399-1835	

(*) At least one of these is mandatory
(**) Mandatory

A.1. Current position

Name of University/Institution	Biosanitary Research Institute, ibs.GRANADA / University Hospitals of Granada / University of Granada		
Department	Microbiology Unit		
Address and Country	Av. de las Fuerzas Armadas, 2, 18014 Granada, Spain		
Phone number		E-mail	jags@genyo.es
Current position	Principal Investigator	From: 2008	
Key words	Molecular and Cellular Biology, drug discovery, drug targeting, nanobody, immunotherapy, G-quadruplex		

A.2. Education

PhD	University	Year
PhD in Pharmacy	University of Granada	1993
Pharmacy degree	University of Granada	1987

A.3. JCR articles, h Index, thesis supervised…(last ten years)

JCR articles: 37; Q1: 32; H Index: 21; total citations: 1729; average citations / year (last 5 years): 836; thesis supervised: 4

Part B. CV SUMMARY *(max. 3500 characters, including spaces)*

I am Principal Investigator and leader of Nanomedicine for Infectious Disease group at IBS, Granada, Spain. My major research focus over the last 25 years has been the molecular and cellular biology of the trypanosomatids. During this period hI have addressed different aspects of the biology of these parasites. Since 2008, as principal investigator at the Infectious diseases unit, University Hospitals in Granada, I started a line of research focused on seeking new therapies and targets treating African trypanosomiasis. In 2009 I participated as a partner of the EU-FP7 consortium Nanotryp. My role was to develop a new drug targeting approach to therapy for African trypanosomiasis using single domain antibodies, known as nanobodies, conjugated to nanoparticles containing trypanocidal drugs. Currently, I am applying this nanobody based technology to others pathogens, such as Influenza virus. I am the coordinator of TARBRAINFEC consortium (EuroNanaMed III 2018, EU H2020)) which aims to develop a drug delivery nanosystem coated with a nanobodies as a proof of concept for targeting brain infections caused by bacteria, virus and parasite. I am also a partner of the 3TR consortium (Innovative Medicines Initiative (IMI2) Programme 14th Call H2020-JTI-IMI2-2018. I was also member of COST Action CM1307 “Targeted chemotherapy towards diseases caused by endoparasites”.

Part C. RELEVANT MERITS

C.1. Publications (including books)

1: Ortiz-Gonzalez M, Pérez-Victoria I, Ramirez-Macias I, de Pedro N, Linde-Rodriguez A, González-Menéndez V, Sanchez-Martin V, Martín J, Soriano-Lerma A, Genilloud O, Perez-Carrasco V, Vicente F, Maceira J, Rodrígues-Poveda CA, Navarro-Marí JM, Reyes F, Soriano M, Garcia-Salcedo JA. Curvicollide D Isolated from the Fungus *Amesia* sp. Kills African Trypanosomes by Inhibiting Transcription. Int J Mol Sci. 2022 May 29;23(11):6107. doi:10.3390/ijms23116107. FI 6.2. Q1.

2: Sanchez-Martin V, Plaza-Calonge MDC, Soriano-Lerma A, Ortiz-Gonzalez M, Linde-Rodriguez A, Perez-Carrasco V, Ramirez-Macias I, Cuadros M, Gutierrez-

Fernandez J, Murciano-Calles J, Rodríguez-Manzaneque JC, Soriano M, Garcia-Salcedo JA. Gallic Acid: A Natural Phenolic Compound Exerting Antitumoral Activities in Colorectal Cancer via Interaction with G-Quadruplexes. Cancers (Basel). 2022;14(11):2648. doi: 10.3390/cancers14112648. FI 6.6. Q1.
3: Cobo F, Pérez-Carrasco V, Rodríguez-Guerrero E, Sampedro A, Rodríguez-Granger J, García-Salcedo JA, Navarro-Marí JM. Misidentification of Phocaeicola (Bacteroides) dorei in two patients with bacteremia. Anaerobe. 2022 Mar 2:102544. doi: 10.1016/j.anaerobe.2022. FI 3.3. Q3.
4: Cobo F, Pérez-Carrasco V, Gómez-Vicente E, Martín-Hita L, García-Salcedo JA, Navarro-Marí JM. Parabacteroides goldsteinii abdominal infection in a patient with lymphoma. Infect Dis Now. 2022;52(2):117-119. doi:10.1016/j.idnow.2021.04.004.
5: Cobo F, Pérez-Carrasco V, Sánchez-Martin V, García-Salcedo JA, Martín EB, Navarro-Marí JM. A rare cause of bacteremia due to Porphyromonas asaccharolytica in a patient with necrotizing fasciitis. Anaerobe. 2021; 71:102442. doi:10.1016/j.anaerobe.2021.102442. FI 3.3. Q3.
6: Soriano-Lerma A, García-Burgos M, Alférez MJM, Pérez-Carrasco V, Sanchez-Martin V, Linde-Rodríguez Á, Ortiz-González M, Soriano M, García-Salcedo JA, López-Aliaga I. Gut microbiome-short-chain fatty acids interplay in the context of iron deficiency anaemia. Eur J Nutr. 2022 ;61(1):399-412. doi:10.1007/s00394-021-02645-6. FI 5.6. Q1
7: Sanchez-Martin V, Soriano M, Garcia-Salcedo JA. Quadruplex Ligands in CancerTherapy. Cancers (Basel). 2021;13(13):3156. doi: 10.3390/cancers13133156.
FI 6.6. Q1.
8: Sanchez-Martin V, Schneider DA, Ortiz-Gonzalez M, Soriano-Lerma A, Linde-Rodriguez A, Perez-Carrasco V, Gutierrez-Fernandez J, Cuadros M, Morales JC, González C, Soriano M, Garcia-Salcedo JA. Targeting ribosomal G-quadruplexes with naphthalene-diimides as RNA polymerase I inhibitors for colorectal cancer reatment. Cell Chem Biol. 2021; 28(11):1590-1601.e4. doi: 0.1016/j.chembiol.2021.05.021. FI 9.03. Q1.
9: Cobo F, Pérez-Carrasco V, González A, Sánchez-Martin V, García-Salcedo JA, Navarro-Marí JM. Bacteremia caused by Anaerococcus SPP: Is this an underdiagnosed infection? Anaerobe. 2021; 70:102405. doi:10.1016/j.anaerobe.2021.102405. FI 3.3. Q3.
10: Perez-Carrasco V, Soriano-Lerma A, Soriano M, Gutiérrez-Fernández J, Garcia-Salcedo JA. Urinary Microbiome: Yin and Yang of the Urinary Tract. Front Cell Infect Microbiol. 2021; 11:617002. doi: 10.3389/fcimb.2021.617002. FI 6.07 Q1.
11: Cobo F, González A, Pérez-Carrasco V, García-Salcedo JA. Pantoea stewartii: A new pathogen as a cause of bacteremia? Enferm Infecc Microbiol Clin (Engl Ed). 2021:S0213-005X(21)00079-3. doi: 10.1016/j.eimc.2021.03.010.
12: Cobo F, Pérez-Carrasco V, Gómez-Vicente E, Martín-Hita L, García-Salcedo JA, Navarro-Marí JM. First case of abdominal infection caused by Bacteroides fluxus. Anaerobe. 2021; 69:102363. doi:10.1016/j.anaerobe.2021.102363. FI 3.3. Q3.
13: Díaz-Faes L, Soriano-Lerma A, Magan-Fernandez A, López M, Gijon J, García-Salcedo JA, Soriano M, Mesa F. Structural and functional microbial patterns in cohabitating family members with history of periodontitis. Oral Dis. 2022. doi:10.1111/odi.13786. FI 3.5. Q1
14: Sanchez-Martin V, Lopez-Pujante C, Soriano-Rodriguez M, Garcia-Salcedo JA. An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer. Int J Mol Sci. 2020;21(23):8900. doi: 10.3390/ijms21238900. FI 6.2. Q1
15: Cobo F, Pérez-Carrasco V, García-Salcedo JA, Navarro-Marí JM. Bacteremia caused by Veillonella dispar in an oncological patient. Anaerobe. 2020; 66:102285. doi: 10.1016/j.anaerobe.2020.102285. FI 3.3. Q3.
16: Cobo F, Foronda C, Pérez-Carrasco V, Martin-Hita L, García-Salcedo JA, Navarro-Marí JM. First description of abdominal infection due to Alistipes onderdonkii. Anaerobe. 2020; 66:102283. doi: 10.1016/j.anaerobe.2020.102283. FI 3.3. Q3.
17: Soriano-Lerma A, Pérez-Carrasco V, Sánchez-Marañón M, Ortiz-González M, Sánchez-Martín V, Gijón J, Navarro-Mari JM, Soriano M, García-Salcedo JA. Influence of 16S rRNA target region on the outcome of microbiome studies in soil and saliva samples. Sci Rep. 2020;10(1):13637. doi: 10.1038/s41598-020-70141-8. FI 4.4 Q1
18. Cobo F, Gómez E, Rodríguez-Granger J, Sampedro A, García-Salcedo JA, Navarro-Marí JM. A rare case of bacteremia caused by Propionibacterium (Propionimicrobium)

lymphophilum. Anaerobe. 2020; 62:102166. doi:10.1016/j.anaerobe.2020.102166. FI 3.3. Q3.
19. Soriano-Lerma A, Magán-Fernández A, Gijón J, Sánchez-Fernández E, Soriano M, García-Salcedo JA, Mesa F. Short-term effects of hyaluronic acid on the subgingival microbiome in peri-implantitis: A randomized controlled clinical trial. Journal of Periodontology. 2019. doi: 10.1002/JPER.19-0184. FI: 6.9. D1 Corresponding autor.
20. Marques J, Valle-Delgado JJ, Urbán P, Baró E, Prohens R, Mayor A, Cisteró P, Delves M, Sinden RE, Grandfils C, de Paz JL, García-Salcedo JA, Fernàndez-Busquets X. Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery. Nanomedicine. 13 - 2, pp. 515 - 525. 2017. doi: 10.3389/fphar.2016.00351. FI 6.5. Q1.
21. Sánchez-Marañón, M Miralles, I, Aguirre-Garrido, J.F., Anguita-Maeso, M., Millán-Casamayor, V., Ortega, R, García-Salcedo, J.A., Martínez-Abarca, F., Soriano, M. Changes in the soil bacterial community along a pedogenic gradient. Scientific Reports. 7 - 1. 14593. 2017. doi: 10.1038/s41598-017-15133-x. FI 4.122. Q1
22. Luque-González, M.A., Tabraue-Chávez, M., Fara, A., López-Longarela, B., López-Delgado, F.J., Guardia-Monteagudo, J.J., Sánchez-Martín, R.M., Ilyine, H., Ortiz-González, M., Miguel Soriano, M., García-Salcedo J.A., Pernagallo, S., Díaz-Mochón, J.J. Identification of Trypanosomatids by detecting Single Nucleotide Fingerprints using DNA analysis by dynamic chemistry with MALDI-ToF. Talanta. 176, pp. 299 - 307. 2017. Doi: 10.1016/j.talanta.2017.07.059. FI 4.24. Q1
23. García Salcedo J. A., Unciti-Broceta JD, Valverde-Pozo J, Soriano, M.
New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites. Frontiers in Pharmacology. 7 - 351, pp. 1 - 14. 2016. doi: 10.3389/fphar.2016.00351. FI 4.4. Q1
24. Arias-Mediano, J. L., Unciti-Broceta, J. D., Maceira, J., del Castillo, T., Hernández-Quero, J., Magez, S., Soriano, M., García-Salcedo, J. A. Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. Journal of controlled release. 197 - 10, pp. 190 - 198. 2015. 10.1016/j.jconrel.2014.11.002. FI 7.44. Q1
25. Pineda de las Infantas y Villatoro MJ, Unciti-Broceta JD, Contreras-Montoya R, Garcia-Salcedo JA, Gallo Mezo MA, Unciti-Broceta A, Diaz-Mochon JJ. Amide-controlled, one-pot synthesis of tri-substituted purines generates structural diversity and analogues with trypanocidal activity. Scientific Reports. 5 - 9139, pp. 1 - 9. 2015. doi: 10.1038/srep09139. FI 5.22. Q1
26. Unciti-Broceta, J. D., Arias-Mediano, J. L., Maceira, J., Soriano, M., Ortiz, M., Hernández-Quero, J., Muñoz-Torres, M. E., de Koning, H. P., Magez, S., García-Salcedo, J. A. Specific cell targeting therapy reverses drug resistance in African trypanosomiasis. PLoS Pathogens. 11 - 6, pp. 1 - 20. 2015. doi: 10.1371/journal.ppat.1004942. FI 7.00. Q1
27. Garcia-Salcedo JA, Unciti-Broceta JD, Soriano M. Could specific cell targeting overcome resistance associated with current treatments for African trypanosomiasis? Nanomedicine. 10 - 24, pp. 3515 - 3517. 2015. doi: 10.2217/nnm.15.167
Índice de impacto: 4.88. Q1
28. García-Fontana B, Morales-Santana S, Longobardo V, Reyes-García R, Rozas-Moreno P, García-Salcedo J. A., Muñoz-Torres M. Relationship between Proinflammatory and Antioxidant Proteins with the Severity of Cardiovascular Disease in Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. 16 - 5, pp. 9469 - 9483. 2015. doi: 10.1007/s00198-013-2462-y. FI 3.25 Q1. Corresponding author
29. Del Castillo T, Morales-Sanfrutos J, Santoyo-González F, Magez S, Lopez-Jaramillo FJ, Garcia-Salcedo JA. Monovinyl Sulfone b-Cyclodextrin: A Flexible Drug Carrier System. ChemMedChem. 9, pp. 383 - 389. 2014. 10.1002/cmdc.201300385
Índice de impacto: 2.97. Q2
30. Garcia-Fontana B, Morales-Santana S, Varsavsky M, García-Martín A, García-Salcedo JA, Reyes-García R, Muñoz-Torres M. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporosis International. 25, pp. 645 - 651. 2014. doi: 10.1007/s00198-013-2462-y.
Índice de impacto: 4.16 Q1
31. Garcia-Salcedo JA, Munday, JC, Unciti-Broceta JD, de Koning HP. Progress Towards New Treatments for Human African Trypanosomiasis. Trypanosomes and Trypanosomiasis. pp. 217 - 238. 2014.

En calidad de: Autor/a o coautor/a de capítulo de libro
32. Rozas Moreno P, Reyes García R, García-Martín A, Varsavsky M, García-Salcedo J A, Muñoz-Torres M. Journal of Endocrinological Investigation. 36 - 1, pp. 16 - 36. 2013. doi: 10.3275/8285. FI 1.55. Q3.
33. Morales-Santana S, García-Fontana B, García-Martín A, Rozas Moreno P, Reyes García R, García-Salcedo J A, Muñoz-Torres M. Atherosclerotic disease in type 2 diabetes is associated with an increase of sclerostin levels. Diabetes Care. 2013. doi: 10.3275/8285. FI 8.57. Q1.
34. Unciti-Broceta J D, Maceira J, Sonia Morales, García-Pérez, A, Muñóz-Torres M, Garcia-Salcedo, J. A. Nicotinamide Inhibits the Lysosomal Cathepsin b-like Protease and Kills African Trypanosomes. Journal of Biological Chemistry. 288 - 15, pp. 10548 - 10557. 2013. FI 4.60. Q1
35. Unciti-Broceta JD, Del Castillo T, Soriano M, Magez S, Garcia-Salcedo JA.
Novel therapy based on camelid nanobodies. Therapeutic Delivery. 4 - 10, pp. 1321 - 1336. 2013. FI 3.1
36. Reyes-Garcia R, Rozas-Moreno P, Jimenez-Moleon J J, Villoslada M J, Garcia-Salcedo J A, Santana-Morales S, Muñoz-Torres M. Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes. Diabetes & Metabolism. 38 - 1, pp. 76 - 157. 2012. FI 2.40. Q2.
37. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 97, pp. 234 - 241. 2012. FI 6.4. Q1.

C.2. Research projects and grants

1. Ref: SAF2006-02854
Title: Validación del citoesqueleto de actina como diana terapéutica antitripanosomal.
Funding entity: Ministerio de Educación y Ciencia; Plan I+D (SAF2006-02854)
From: 1-1-2007 to: 31-12- 2008
Role: principal investigator:
Buget: 33.880 €
2. Ref: FP7-HEALTH-2007-B-2.3.4-1.223048
Título: Exploiting Nanobodies in development of new diagnostic tools and treatment methods for African Trypanosomiasis.
Funding entity: European Unión Europea. 7th Frame Programme I+D. FP7-HEALTH-2007.
From 2009 to 2013
Coordinador: Stefan Magez
Role: IP of Work Package 5
Total buget for the group: 586.900 €
3. Ref: SAF2011-30528
Title: New therapies for human African trypanosomiasis
Fundingl entity: Ministry of Economy and competitiveness, R & D Plan.
From: 2012 to 2015
Principal Investigator: Jose A Garcia-Salcedo
Total budget: 120,800 €
4. Ref: SAF2015-71714-R
Title: Development of nanobody based therapy against flu virus.
Funding entity: Ministry of Economy and competitiveness, R & D Plan.
From: 2016 to 2018
Role: principal Investigator:
Total Bbudget: 145,800 €
5. Ref: TARBRAINFEC AC18/00008
Title: Nanosystems conjugated with antibody fragments for treating brain infections. EuroNanoMed (ERA-Net Cofund Action on Nanomedicine under Horizon 2020.
Funding entity: Instituto de Salud Carlos III
From 2019 to 2021.
Coordinator: Jose A García-Salcedo
Total budget: 1.063.695 €

Total budget for the group; 199.045 €
6 Ref: 3TR, 831434.
Title: Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Funding entity: Innovative Medicines Initiative (IMI2) Programme 14th Cal, EU. H2020-JTI-IMI2-2018.
Coordinator: Martan Alarcón-Riquelme
From 2019 to 2026
Total budget: 40.063.695 €
Total budget for the group; 221.250 €
Role: Principal Investigator
7 Ref: PI21/00497
Title Producción de anticuerpos terapéuticos para el tratamiento de la COVID-19
Financial entity Acción Estratégica en Salud, ISCIII
From 2022 to2024.
Investigador Principal: José Antonio García Salcedo
Awarded Budget 87.120 €
8. Ref: PLEC2021-008094.
Title: New targets and designs to improve CAR-T cell based immunotherapy against pancreatic cancer.
Financial entity Nex generatio EU, Plan de Recuperación Trans formación y Resiliencia, Agencia Estatal de Investigación.
From 2021 to 2024.
Investigador Principal: José Antonio García Salcedo
Awarded Budget 76.492 €

C.4. Patents

Title: Sistema para el transporte de moléculas biologicamente activas que comprende una nanoparticula, un peptido y una molecula biologicamente activa.
Inventors: García Salcedo, Jose Antonio; Hernández Quero, José; Unciti Broceta, Juan Diego; Maceira Pena José; Del Castillo Santaella, Teresa; Soriano Rodríguez, Miguel; Arias Mediano, José Luis; Ruiz Martínez, María Adolfina.
Assignee: Fundación para la Investigación Biosanitaria en Andalucía Oriental. FIBAO
Country: España
Status:
- National Patent Application P201231367.
- International Patent Application PCT / ES2013 / 070619.
- International patent publication WO201403334